What it is

You know exactly when it started. You can name the month, maybe the week. You got COVID, you were supposed to recover, and something didn't come back online.

Long COVID — formally called Post-Acute Sequelae of SARS-CoV-2 Infection, or PASC — is a multi-system condition in which symptoms persist or develop after the acute phase of COVID-19 infection has resolved. Symptoms may linger from the original infection or appear weeks after initial recovery. They can affect nearly every organ system.

The CDC defines Long COVID as symptoms lasting four or more weeks after infection. Most researchers working directly with patients use a broader framework — symptoms that are new, returning, or ongoing beyond the expected recovery window, that were not present before infection, and that cannot be explained by another diagnosis.

The fatigue isn't laziness. The brain fog isn't stress. The crash after a short walk isn't deconditioning. These are documented biological phenomena — and the research is finally building the evidence base to show it.

Symptoms

Long COVID is not a single-symptom condition. The symptom profile is broad, varies significantly from person to person, and can shift over time. Some symptoms improve. Some persist for months or years. Some appear well after the acute infection has resolved.

Most commonly reported:

• Fatigue — not ordinary tiredness. Profound, unrelenting exhaustion that does not improve with rest

• Post-exertional malaise (PEM) — worsening of symptoms after physical or cognitive exertion. This is the defining feature shared with ME/CFS and its presence changes everything about the correct management approach

• Brain fog — difficulty with memory, concentration, word-finding, processing speed

• Breathlessness — shortness of breath disproportionate to exertion level

• Chest pain and palpitations

• Headache

• Sleep disruption — unrefreshing sleep, insomnia

• Joint and muscle pain

• Orthostatic intolerance — symptoms that worsen upright and improve lying down. Significant overlap with POTS and dysautonomia

• Sensory changes — altered taste and smell, which may persist or fluctuate long after infection

• Gastrointestinal symptoms

• Anxiety and depression — both as direct neurological effects and as entirely understandable responses to a chronic, disabling, poorly understood illness

The presence of post-exertional malaise in a significant portion of Long COVID patients is one of the most important clinical findings of the past several years. It changes what the correct management approach looks like entirely — and rules out approaches that would otherwise seem reasonable.

History — How We Got Here

COVID-19 was first identified in late 2019. By mid-2020, clinicians were beginning to document patients who had survived the acute infection but were not recovering on the expected timeline. The term Long Haulers emerged from patient communities before the medical system had a formal name for what was happening.

Post-viral illness — persistent symptoms following a viral infection — is not new. It has been documented following mononucleosis, Ross River virus, chikungunya, giardia, Q fever, and other infections for decades. What was different about Long COVID was scale. Enough people were affected simultaneously that the pattern could not be dismissed, minimized, or attributed to anxiety at the population level.

The 2021 WHO definition set a formal threshold: symptoms occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, lasting at least two months, not explained by an alternative diagnosis. The U.S. government recognized Long COVID as a disability under the Americans with Disabilities Act in 2021.

The NIH launched the RECOVER initiative the same year — a multi-billion-dollar effort to study Long COVID mechanisms and develop treatment approaches. This represented a scale of research investment in post-viral illness that the ME/CFS community, fighting for the same recognition for decades, had never seen.

What Long COVID forced the medical system to acknowledge:

• Viral infection can cause lasting multi-system dysfunction beyond the acute phase

• Post-exertional malaise is a real physiological phenomenon, not deconditioning

• Normal labs do not mean nothing is wrong

• Patients describing these symptoms were not making them up

These are things the ME/CFS community had been saying for forty years. Long COVID did not discover post-viral illness. It forced the institutions with the budget to take it seriously.

What the Research Shows — Mechanisms

Long COVID is not a single disease with a single cause. Current research points to several overlapping mechanisms, and individual patients may be driven by different combinations of them.

Viral persistence. SARS-CoV-2 viral fragments — and in some cases intact replicating virus — have been detected in multiple tissue types months after acute infection. The gut reservoir appears particularly significant. Persistent antigen may continue driving immune activation long after the respiratory infection has resolved.

Immune dysregulation. Long COVID patients show evidence of immune system abnormalities including altered T cell profiles, elevated inflammatory markers, and activation of autoimmune processes. The immune system appears to remain in a state of dysregulated activation.

Autoantibodies. Studies have identified autoantibodies — antibodies that attack the body's own tissues — in a subset of Long COVID patients. These include autoantibodies against receptors involved in autonomic nervous system function, which may explain some of the cardiovascular and dysautonomia symptoms.

Latent herpesvirus reactivation. EBV reactivation has been documented in a subset of Long COVID patients. This is one of the most clinically relevant findings — and one of the most important distinctions between Long COVID and ME/CFS. A 2025 study measuring viral load in sputum samples found significantly elevated EBV in ME/CFS patients compared to controls — but did not find the same pattern in Long COVID patients. Same clinical picture in many ways. Different viral architecture underneath. Treatment research for one may not translate directly to the other.

Microclots and vascular dysfunction. Researchers have documented the presence of microclots — small fibrin clots resistant to normal breakdown — in Long COVID patients. These may impair oxygen delivery at the tissue level and help explain the fatigue and post-exertional symptoms.

Neurovascular dysregulation. Overlapping research in Long COVID and ME/CFS has documented endothelial dysfunction, impaired venous return, and microcirculatory abnormalities. The crash after exertion is not psychological — there is documented tissue hypoxia and circulatory dysfunction at the physiological level.

I'm not a doctor. I'm not telling you to change your medication. The mechanisms above are documented in peer-reviewed research and are presented for information purposes. Always work with a qualified physician.

The ME/CFS Overlap — and the Critical Distinction

A significant portion of Long COVID patients — estimates range from 30 to 50 percent in some studies — meet the diagnostic criteria for ME/CFS. The symptom profiles overlap substantially: post-exertional malaise, profound fatigue, unrefreshing sleep, cognitive impairment, orthostatic intolerance.

This overlap matters for two reasons. First, management strategies developed for ME/CFS — particularly around pacing and avoiding PEM — are directly applicable to Long COVID patients who show this pattern. Second, approaches that have been shown to harm ME/CFS patients — particularly graded exercise therapy — carry the same risk of harm in Long COVID patients with PEM.

The key distinction: ME/CFS can be triggered by many different viral and infectious events — EBV, enteroviruses, and others documented over decades. Long COVID has one known trigger: SARS-CoV-2. The 2025 sputum research found elevated EBV in ME/CFS patients on crash days — but not in Long COVID patients. Same clinical picture in many ways. Different viral architecture underneath. These are related but distinct conditions.

Some Long COVID patients recover partially over time. Full ME/CFS recovery is less common. This distinction matters for prognosis — but should be delivered honestly, without false hope and without unnecessary pessimism.

What you can do about it

There is no FDA-approved treatment for Long COVID. Anyone selling a cure is lying. What exists is management — reducing symptom triggers, protecting remaining function, and treating individual symptoms where possible.

Pacing. For patients with post-exertional malaise, pacing is the most evidence-supported management strategy available. Stay within your energy envelope — not pushing to increase tolerance through exposure. The goal is to reduce PEM events, not build endurance through them. See the ME/CFS page for a full discussion of pacing methodology.

Avoid graded exercise therapy if PEM is present. GET has been removed from CDC ME/CFS guidelines following evidence of patient harm. The same caution applies to Long COVID patients with PEM. If a provider recommends a progressive exercise program without first establishing whether PEM is present, that is a significant gap in the assessment.

Heart rate monitoring. Some patients use heart rate as a proxy for exertion threshold. Staying below roughly 50-60% of maximum heart rate may reduce PEM risk. Individual thresholds vary. This is a tool, not a cure.

Orthostatic intolerance management. Increased fluid and sodium intake, compression garments, and careful position changes can help manage dysautonomia symptoms. Tilt table testing or the NASA lean test can confirm whether orthostatic intolerance is part of the picture.

Symptom-specific treatment. Sleep disruption, pain, headache, and other individual symptoms can sometimes be addressed with a knowledgeable physician. This is management of individual symptoms, not treatment of the underlying condition. It matters anyway.

Ongoing research. The NIH RECOVER initiative and numerous independent research programs are actively pursuing Long COVID treatments. Clinical trials are enrolling. Stay connected to reliable patient advocacy organizations for updates as they develop.

Asking for the right tests

There is no single test that diagnoses Long COVID. Diagnosis is primarily clinical — symptom history following confirmed or probable SARS-CoV-2 infection, after ruling out other conditions.

If you are pursuing evaluation, ask for:

• COVID serology — to confirm prior infection if not previously documented

• Complete thyroid panel: TSH, Free T4, Free T3, TPO antibodies. Not TSH alone. Thyroid dysfunction can be triggered or unmasked by viral illness.

• Complete metabolic panel and CBC with differential

• Vitamin D, B12, and folate — deficiencies are common and treatable

• ANA screen — to begin ruling out autoimmune processes

• Ferritin — elevated in some post-viral inflammatory states

• Tilt table test or NASA lean test — if orthostatic intolerance symptoms are present

• Referral to a Long COVID clinic — specialty programs exist with staff who understand the current research. Patient advocacy organizations maintain provider lists.

A normal result is not a clearance. Many Long COVID patients have labs that read as unremarkable. Normal labs in the presence of debilitating symptoms means the tests being run are not capturing what is happening — not that nothing is happening.

Personal note

I never had COVID — confirmed by negative serology. So everything on this page is observational: watching Long COVID arrive, watching the communities form, and recognizing the pattern immediately.

I watched people describe their crash days in Long COVID groups and read it like a mirror. The fatigue that doesn't respond to rest. The PEM that comes 24 hours later, not immediately. The brain fog that makes a paragraph feel like a wall. The labs that come back normal while you can't make it to the kitchen.

I also watched them get dismissed in some of the same ways ME/CFS patients had been dismissed for decades — until there were simply too many of them for the system to ignore.

The ME/CFS community built the framework that Long COVID patients needed. The Long COVID wave brought the research funding that ME/CFS patients deserved all along. Both things are true. The timing is brutal and the debt is real.

If you are in that waiting room hoping the next test will come back with something that at least has a treatment protocol — you are not alone. That thought is more common than anyone says out loud. You are not broken for having it.

Sources

• CDC — Long COVID or Post-COVID Conditions: cdc.gov/coronavirus/2019-ncov/long-term-effects

• NIH RECOVER Initiative — recovercovid.org

• WHO — Post COVID-19 condition (Long COVID) technical brief: who.int

• Davis et al. (2023) — Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. — PubMed PMID: 36639608

• Pretorius et al. (2021) — Persistent clotting protein pathology in Long COVID/PASC. Cardiovascular Diabetology. — PubMed PMID: 34348715

• Systrom et al. — Exercise Pathophysiology in ME/CFS and PASC. CHEST Journal. — PubMed PMC10088277

• MDPI Viruses (2025) — Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from ME/CFS Patients (includes comparative Long COVID data)

• JCI (2021) — Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome — doi:10.1172/JCI150377

• Frontiers in Immunology (2025) — The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity

• 2015 Institute of Medicine Report — Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness — NAP.edu